Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies.

Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, Sun H, Walter M, Wei G, Smith DL, Sun X, Fei F, Xie J, Panagopoulou TI, Chen CW, Song JY, Aldoss I, Kayembe C, Sarno L, Müschen M, Inghirami GG, Forman SJ, Kwak LW.

Sci Transl Med. 2019 Sep 25;11(511). pii: eaaw9414. doi: 10.1126/scitranslmed.aaw9414.

PMID:
31554741
2.

Targeting myeloid-derived suppressor cells for cancer immunotherapy.

Liu Y, Wei G, Cheng WA, Dong Z, Sun H, Lee VY, Cha SC, Smith DL, Kwak LW, Qin H.

Cancer Immunol Immunother. 2018 Aug;67(8):1181-1195. doi: 10.1007/s00262-018-2175-3. Epub 2018 May 31. Review.

PMID:
29855694
3.

Novel BAFF-Receptor Antibody to Natively Folded Recombinant Protein Eliminates Drug-Resistant Human B-cell Malignancies In Vivo.

Qin H, Wei G, Sakamaki I, Dong Z, Cheng WA, Smith DL, Wen F, Sun H, Kim K, Cha S, Bover L, Neelapu SS, Kwak LW.

Clin Cancer Res. 2018 Mar 1;24(5):1114-1123. doi: 10.1158/1078-0432.CCR-17-1193. Epub 2017 Nov 27.

Supplemental Content

Loading ...
Support Center